Noble Financial Brokers Decrease Earnings Estimates for UNCY

Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report) – Noble Financial dropped their FY2026 earnings per share (EPS) estimates for Unicycive Therapeutics in a research report issued to clients and investors on Tuesday, November 17th. Noble Financial analyst R. Leboyer now expects that the company will earn ($0.80) per share for the year, down from their previous forecast of ($0.62). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.14) per share. Noble Financial also issued estimates for Unicycive Therapeutics’ Q4 2026 earnings at ($0.33) EPS.

A number of other equities analysts have also recently issued reports on the stock. HC Wainwright dropped their price target on shares of Unicycive Therapeutics from $15.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, September 29th. B. Riley Financial reiterated a “buy” rating and issued a $20.00 target price (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Guggenheim reiterated a “buy” rating and set a $25.00 price target (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday, August 13th. Zacks Research upgraded shares of Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Benchmark reiterated a “speculative buy” rating and set a $15.00 target price (up from $13.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 20th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $18.25.

Read Our Latest Report on UNCY

Unicycive Therapeutics Stock Performance

Shares of NASDAQ UNCY opened at $3.57 on Thursday. The company has a 50 day simple moving average of $4.11 and a two-hundred day simple moving average of $5.89. The company has a market capitalization of $104.19 million, a price-to-earnings ratio of -2.14 and a beta of 1.91. Unicycive Therapeutics has a fifty-two week low of $3.33 and a fifty-two week high of $8.74.

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last announced its quarterly earnings data on Monday, November 16th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.10.

Institutional Trading of Unicycive Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in UNCY. Pinnacle Wealth Planning Services Inc. purchased a new position in shares of Unicycive Therapeutics during the third quarter valued at about $36,000. Renaissance Technologies LLC bought a new stake in shares of Unicycive Therapeutics in the first quarter worth about $161,000. Chicago Partners Investment Group LLC lifted its position in shares of Unicycive Therapeutics by 26.0% in the third quarter. Chicago Partners Investment Group LLC now owns 26,966 shares of the company’s stock worth $105,000 after buying an additional 5,556 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock worth $194,000 after buying an additional 29,378 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Unicycive Therapeutics in the second quarter worth about $248,000. Institutional investors own 40.42% of the company’s stock.

Key Headlines Impacting Unicycive Therapeutics

Investors following UNCY have been watching these headlines:

  • Positive Sentiment: HC Wainwright raised its estimates for several periods, including FY2026 EPS to ($1.13) from ($1.38) and FY2027 to ($0.71) from ($0.86), while maintaining a Buy rating and $13 price target. The improved estimates could support sentiment. MarketBeat
  • Neutral Sentiment: Brookline Capital Markets issued markedly more optimistic long-range forecasts, projecting positive EPS from FY2027 onward. These are analyst projections and differ substantially from HC Wainwright’s outlook, so they add uncertainty rather than a clear consensus signal. MarketBeat
  • Negative Sentiment: Noble Financial lowered its FY2026 EPS estimate to ($0.80) from ($0.62), including a deeper projected Q4 loss. HC Wainwright also cut its FY2028–FY2030 EPS forecasts substantially, although it retained its Buy rating and $13 target; these longer-term reductions may weigh on investor expectations. MarketBeat

About Unicycive Therapeutics

(Get Free Report)

Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.

Read More

Earnings History and Estimates for Unicycive Therapeutics (NASDAQ:UNCY)

Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.